Logo

Pfizer Reports Launch Date for its Two Anticancer Biosimilars

Share this

Pfizer Reports Launch Date for its Two Anticancer Biosimilars

Shots:

  • Pfizer’s two anticancer biosimilar Trazimera and Ruxience will be launched in Jan 2020- while the other in Feb 2020 respectively
  • Ruxience (biosimilar- rituximab) was approved in July 2019 targeted for the treatment of non-Hodgkin lymphoma- chronic lymphocytic leukemia- and granulomatosis with polyangiitis and microscopic polyangiitis while Trazimera (biosimilar- trastuzumab) received approval in Mar’2019 for HER2-positive breast cancer and metastatic gastric cancer  
  • Ruxience (rituximab-pvvr) is a mAb designed to target CD20 protein and is Pfizer’s third oncology biosimilar approved by the US FDA in 2019 with EMA’s awaited approval. Trazimera (trastuzumab-qyyp) is a mAb designed to target HER2 protein and has been evaluated in 500 patients in 20+ countries to date

Click here to­ read full press release/ article | Ref: Center for Biosimilars | Image: Twitter


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions